Phase III TOWER Substudy: Blinatumomab Shows Health-Related QoL Benefit vs Chemotherapy in R/R Ph- B-Precursor ALL

Slideset - In this subanalysis of the phase III TOWER study, blinatumomab demonstrated superior health-related QoL vs standard-of-care chemotherapy in patients with R/R Ph- B-Precursor ALL.
Source: Clinical Care Options Leukemia - Category: Hematology Source Type: research